IVRN — Innoveren Scientific Share Price
- $0.00m
- $5.58m
- $0.45m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 7.88 | 8.35 | 2.15 | 1.61 | 0.45 | n/a | n/a | 16.94% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Innoveren Scientific Inc. is a life science and biotech incubator company. The Company is focused on advancing new technologies in areas of unmet need across multiple indications for improving patient lives. The Company is also focused on investing in and fosters technologies that are supported by a scientific foundation.
Directors
- Raymond Monteleone CHM (73)
- Michael Yurkowsky CEO (47)
- Jeremy Daniel CFO (44)
- Tanya Rhodes CTO
- William Horne DRC (66)
- Matthew Anderer IND (55)
- Richard Rosenblum IND (62)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- July 30th, 2013
- Public Since
- December 19th, 2014
- No. of Employees
- 26
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 712,710
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 151 W4th St, Ste 223, CINCINNATI, 45202
- Web
- http://www.hcyte.com/
- Phone
- +1 4043936989
- Auditors
- Frazier & Deeter, LLC
Upcoming Events for IVRN
Q2 2024 Innoveren Scientific Inc Earnings Release
Similar to IVRN
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 21:20 UTC, shares in Innoveren Scientific are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Innoveren Scientific last closed at $0.00 and the price had moved by -99.86% over the past 365 days. In terms of relative price strength the Innoveren Scientific share price has underperformed the S&P500 Index by -99.88% over the past year.
There is no consensus recommendation for this security.
Innoveren Scientific does not currently pay a dividend.
Innoveren Scientific does not currently pay a dividend.
Innoveren Scientific does not currently pay a dividend.
To buy shares in Innoveren Scientific you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Innoveren Scientific had a market capitalisation of $0.00m.
Here are the trading details for Innoveren Scientific:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: IVRN
Based on an overall assessment of its quality, value and momentum Innoveren Scientific is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Innoveren Scientific. Over the past six months, its share price has underperformed the S&P500 Index by -98.64%.
As of the last closing price of $0.00, shares in Innoveren Scientific were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Innoveren Scientific PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Innoveren Scientific's management team is headed by:
- Raymond Monteleone - CHM
- Michael Yurkowsky - CEO
- Jeremy Daniel - CFO
- Tanya Rhodes - CTO
- William Horne - DRC
- Matthew Anderer - IND
- Richard Rosenblum - IND